Alkermes (ALKS) shifts to fully integrated biopharma, leveraging Vibrance-2, Lybalvi growth, and Avadel buy to de-risk ...

Chinese stock charts reach a turning point. What to watch. Investors often look to January for clues about institutional intent, and this year’s opening sent a notable signal in China. ratio chart ...

American Tower (AMT) looks undervalued with stable recurring revenue, a 3.87% yield, and AI/data tailwinds—see why it’s a Buy ...